Implant therapy on patients treated with oral bisphosphonates


Submitted: 8 June 2017
Accepted: 8 June 2017
Published: 30 March 2012
Abstract Views: 522
PDF: 354
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Aris Petros Tripodakis Associate Professor, Department of Prosthodontics and Department of Oral Medicine and Pathology, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
  • Georgios Kamperos Postgraduate Student, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
  • Nikolaos Nikitakis Assistant Professor, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
  • Alexandra Sklavounou-Andrikopoulou Professor, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
Aim Bisphosphonates represent a group of drugs with a significant effect on bone structure preventing bone remodelling. They can be administered for the treatment of osteoporosis, Paget€™s disease, osteogenesis imperfecta, osteopenia and bone metastases. The aim of this study was to discuss the necessary precautions for successful implant therapy on patients treated with per os bisphosphonates. Case reports Two female patients, both in the seventh decade of life, requested implant therapy. Their medical history was significant for osteoporosis, managed with per os bisphosphonates (Risedronate and Alendronate, respectively), without other risk factors for osteonecrosis. The duration of bisphosphonate administration was 4 years and 2 months respectively. After consultation with the treating physician, the patients stopped the bisphosphonates 3 months before and 3 months after the placement of the implants. The patients received antibiotic coverage for the surgical interventions. The treatment plan was completed uneventfully with placement of fixed prostheses without complications during a 2-year follow-up period. Conclusion The greatest dental treatment-related risk for patients on bisphosphonate therapy is bisphosphonate-associated osteonecrosis, which presents with exposure of avascular bone of the jaws and, according to the clinical stage, pain, inflammation, fractures and/or extensive osteolysis. Most of reported cases of bisphosphonate-associated osteonecrosis consist of patients on intravenous drug therapy who had undergone dentoalveolar surgery. Patients on per os bisphosphonates may undergo all types of dentoalveolar surgery, including implant placement, as long as the necessary precautions (bisphosphonate discontinuation, antibiotic coverage, meticulous oral hygiene) are taken.

Supporting Agencies


Petros Tripodakis, A., Kamperos, G., Nikitakis, N., & Sklavounou-Andrikopoulou, A. (2012). Implant therapy on patients treated with oral bisphosphonates. Journal of Osseointegration, 4(1), 9–14. https://doi.org/10.23805/jo.2012.04.01.02

Downloads

Download data is not yet available.

Citations